FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165543889> ?p ?o ?g. }

• W2165543889 endingPage "2190" @default.
• W2165543889 startingPage "2186" @default.
• W2165543889 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jun 2004A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSis corrected byRE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSRE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS RICHARD J. SYLVESTER, WILLEM OOSTERLINCK, and ADRIAN P.M. van der MEIJDEN RICHARD J. SYLVESTERRICHARD J. SYLVESTER More articles by this author , WILLEM OOSTERLINCKWILLEM OOSTERLINCK More articles by this author , and ADRIAN P.M. van der MEIJDENADRIAN P.M. van der MEIJDEN More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000125486.92260.b2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined if 1 immediate instillation of chemotherapy after transurethral resection (TUR) decreases the risk of recurrence in patients with stage Ta T1 single and multiple bladder cancer overall and separately. Materials and Methods: A meta-analysis was performed of the published results of randomized clinical trials comparing TUR alone to TUR plus 1 immediate instillation of chemotherapy. Results: Our study included 7 randomized trials with recurrence information on 1,476 patients. Based on a median followup of 3.4 years and a maximum of 14.5 years, 267 of 728 patients (36.7%) receiving 1 postoperative instillation of epirubicin, mitomycin C, thiotepa or (2′R)-4′-O-tetrahydropyranyl-doxorubicin (pirarubicin) had recurrence compared to 362 of 748 patients (48.4%) with TUR alone, a decrease of 39% in the odds of recurrence with chemotherapy (OR 0.61, p <0.0001). Patients with a single tumor (OR 0.61) and those with multiple tumors (OR 0.44) benefited. However, after 1 instillation 65.2% of patients with multiple tumors had recurrence compared to 35.8% of patients with single tumors, showing that 1 instillation alone is insufficient treatment for patients with multiple tumors. Conclusions: One immediate intravesical instillation of chemotherapy significantly decreases the risk of recurrence after TUR in patients with stage Ta T1 single and multiple bladder cancer. It is the treatment of choice in patients with a single, low risk papillary tumor and is recommended as the initial treatment after TUR in patients with higher risk tumors. References 1 The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol1985; 57: 680. Google Scholar 2 The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol1994; 73: 632. Google Scholar 3 : Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J1988; 296: 1759. Google Scholar 4 : The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol1996; 155: 1233. Link, Google Scholar 5 : A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol1993; 149: 749. Link, Google Scholar 6 : Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol1997; 79: 731. Google Scholar 7 : Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol1999; 161: 1120. Link, Google Scholar 8 : Transurethral resection with perioperative instillation on interferon-α or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-FinnBladder III. J Urol1999; 161: 1133. Link, Google Scholar 9 : Perioperative single dose instillation of epirubicin or interferon- αafter transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence a prospective randomized multicenter study—Finnbladder III long-term results. J Urol2002; 168: 981. Link, Google Scholar 10 : Randomized study of single early instillation of (2′R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer2002; 94: 2363. Google Scholar 11 : A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. Br J Urol1981; 53: 585. Crossref, Medline, Google Scholar 12 : Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol1976; 48: 55. Crossref, Medline, Google Scholar 13 : Single-dose intravesical epodyl after TUR of Ta TCC bladder carcinoma. World J Urol1983; 1: 89. Crossref, Google Scholar 14 : Epirubicina endovesicale nella profilassi delle recidive dei tumori superficiali della vesica. Studio multicentrico, randomizzato. Acta Urol Ital1990; 1: 331. Google Scholar 15 : Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol1983; 129: 505. Link, Google Scholar 16 : Guidelines on bladder cancer. Eur Urol2002; 41: 105. Crossref, Medline, Google Scholar 17 : Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol2002; 41: 523. Google Scholar 18 : Intravesical chemotherapy with epirubicin: a dose response study. J Urol1999; 161: 1490. Link, Google Scholar 19 : Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer1980; 46: 1158. Crossref, Medline, Google Scholar 20 Whelan P., Griffiths G., Stower M., Wallace D., Hetherington J., Hargreave T. et-al.: Preliminary results of a MRC randomised controlled trial of post-operative irrigation of superficial bladder cancer. In: Proceedings of the American Society of Clinical Oncology, vol. 20, abstract 708, 2001 Google Scholar 21 : Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol2002; 42: 167. Google Scholar 22 : Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol1995; 153: 934. Link, Google Scholar 23 : Resultados de un estudio de quimioprofilaxis intravesical, prospectivo, doble aleatorio, entre dos drogas: la adriamicina y el mitomycin; y dos modos de iniciar las instilaciones: precoz y tardio. Efecto sobre la recidiva y la progresion. Arch Esp de Urol1992; 45: 1001. Google Scholar From the European Organization for the Research and Treatment of Cancer Data Center, Brussels, the Universitair Ziekenhuis Gent, Gent, Belgium, and the Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byColeman J, Clark P, Bixler B, Buckley D, Chang S, Chou R, Hoffman-Censits J, Kulkarni G, Matin S, Pierorazio P, Potretzke A, Psutka S, Raman J, Smith A and Smith L (2023) Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO GuidelineJournal of Urology, VOL. 209, NO. 6, (1071-1081), Online publication date: 1-Jun-2023.Tan H (2021) Editorial CommentJournal of Urology, VOL. 207, NO. 2, (300-301), Online publication date: 1-Feb-2022.Steinmetz A, Gantz J, Fiscella K and Messing E (2021) Improving Rates of Immediate Postoperative Intravesical Chemotherapy with Gemcitabine for Low-Grade Bladder Cancer: An Implementation AnalysisUrology Practice, VOL. 9, NO. 1, (47-55), Online publication date: 1-Jan-2022.Cary C, Militello L, DeChant P, Frankel R, Koch M and Weiner M (2020) Barriers to Single-Dose Intravesical Chemotherapy in Nonmuscle Invasive Bladder Cancer—What's the Problem?Urology Practice, VOL. 8, NO. 2, (291-297), Online publication date: 1-Mar-2021.Mossanen M, Ingham M, Leow J, Tinay I, Wang Y, Krasnow R, Preston M, Bellmunt J, Chung B, Rosenberg J and Chang S (2017) Exploring Patterns of Mitomycin C Use in Community Practice UrologyUrology Practice, VOL. 5, NO. 1, (7-14), Online publication date: 1-Jan-2018.Matsumoto K, Matsui Y, Negoro H, Terada N, Yamasaki T, Inoue T, Kamba T, Ogawa O and Kobayashi T (2016) Guideline Adherence of Immediate Post-Transurethral Resection Intravesical Chemotherapy for Patients with Nonmuscle Invasive Bladder CancerUrology Practice, VOL. 3, NO. 6, (456-461), Online publication date: 1-Nov-2016.Raheem O, Liss M and Buckley J (2016) Therapeutic Use of Mitomycin C for Urological Conditions: Systematic Review of the LiteratureUrology Practice, VOL. 3, NO. 4, (283-288), Online publication date: 1-Jul-2016.Cusano J, Haddock P, Jackson M, Luk M, Wiener S, Cox A and Meraney A (2015) Process Improvements Positively Impact the Use of Intravesical Mitomycin C after Transurethral Resection of Nonmuscle Invasive Bladder Cancer in a Large, Urban Urology PracticeUrology Practice, VOL. 2, NO. 6, (291-297), Online publication date: 1-Nov-2015.Rose A, El-Leithy T, Dorp F, Zakaria A, Eisenhardt A, Tschirdewahn S and Rübben H (2015) Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation StudyJournal of Urology, VOL. 194, NO. 4, (939-943), Online publication date: 1-Oct-2015.McKiernan J, Holder D, Ghandour R, Barlow L, Ahn J, Kates M, Badalato G, Roychoudhury A, Decastro G and Benson M (2014) Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment FailureJournal of Urology, VOL. 192, NO. 6, (1633-1638), Online publication date: 1-Dec-2014.Mostafid H, Kirby R, Fitzpatrick J and Bryan R (2014) The Safe and Economical Care of Ta Bladder CancerUrology Practice, VOL. 1, NO. 4, (176-183), Online publication date: 1-Nov-2014.Black P (2014) Bladder Tumor Resection: Doing it RightJournal of Urology, VOL. 191, NO. 6, (1646-1647), Online publication date: 1-Jun-2014.Richards K, Smith N and Steinberg G (2014) The Importance of Transurethral Resection of Bladder Tumor in the Management of Nonmuscle Invasive Bladder Cancer: A Systematic Review of Novel TechnologiesJournal of Urology, VOL. 191, NO. 6, (1655-1664), Online publication date: 1-Jun-2014.Barocas D, Liu A, Burks F, Suh R, Schuster T, Bradford T, Moylan D, Knapp P, Murtagh D, Morris D, Dunn R, Montie J and Miller D (2013) Practice Based Collaboration to Improve the Use of Immediate Intravesical Therapy after Resection of Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 190, NO. 6, (2011-2016), Online publication date: 1-Dec-2013.Filson C, Hollingsworth J, Clemens J and Wei J (2013) The Efficacy and Safety of Combined Therapy with α-Blockers and Anticholinergics for Men with Benign Prostatic Hyperplasia: A Meta-AnalysisJournal of Urology, VOL. 190, NO. 6, (2153-2160), Online publication date: 1-Dec-2013.Falke J, Lammers R, Arentsen H, Ravic M, Pozzi R, Cornel E, Vergunst H, de Reijke T and Witjes J (2012) Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 189, NO. 6, (2077-2082), Online publication date: 1-Jun-2013.Burks F, Liu A, Suh R, Schuster T, Bradford T, Moylan D, Knapp P, Murtagh D, Dunn R, Montie J and Miller D (2012) Understanding the Use of Immediate Intravesical Chemotherapy for Patients with Bladder CancerJournal of Urology, VOL. 188, NO. 6, (2108-2113), Online publication date: 1-Dec-2012.Lee C, Barocas D, Globe D, Oefelein M, Colayco D, Bruno A, O'Day K and Bramley T (2012) Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer CasesJournal of Urology, VOL. 188, NO. 6, (2114-2119), Online publication date: 1-Dec-2012.Cookson M, Chang S, Oefelein M, Gallagher J, Schwartz B and Heap K (2012) National Practice Patterns for Immediate Postoperative Instillation of Chemotherapy in Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 187, NO. 5, (1571-1576), Online publication date: 1-May-2012.Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A (2011) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, VOL. 186, NO. 6, (2158-2167), Online publication date: 1-Dec-2011.Rosevear H, Lightfoot A, Nepple K and O'Donnell M (2010) Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guérin Plus Interferon-αJournal of Urology, VOL. 185, NO. 1, (67-71), Online publication date: 1-Jan-2011.Kamat A and Lotan Y (2009) Perioperative Intravesical Therapy After Transurethral Resection for Bladder CancerJournal of Urology, VOL. 183, NO. 1, (19-20), Online publication date: 1-Jan-2010.Wu W, Ke H, Yang Y, Li C, Chou Y and Huang C (2009) Should Patients With Primary Upper Urinary Tract Cancer Receive Prophylactic Intravesical Chemotherapy After Nephroureterectomy?Journal of Urology, VOL. 183, NO. 1, (56-61), Online publication date: 1-Jan-2010.Ham W, Kim W, Jeon H, Lee D and Choi Y (2009) Long-Term Outcome of Simultaneous Transurethral Resection of Bladder Tumor and Prostate in Patients With Nonmuscle Invasive Bladder Tumor and Bladder Outlet ObstructionJournal of Urology, VOL. 181, NO. 4, (1594-1599), Online publication date: 1-Apr-2009.Sylvester R, Oosterlinck W and O'Donnell M (2008) Re: Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled StudyJournal of Urology, VOL. 181, NO. 1, (410-410), Online publication date: 1-Jan-2009.Oosterlinck W and Sylvester R (2008) Re: A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small RecurrencesJournal of Urology, VOL. 180, NO. 5, (2255-2256), Online publication date: 1-Nov-2008.Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S and Bartoletti R (2008) Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled StudyJournal of Urology, VOL. 180, NO. 1, (110-115), Online publication date: 1-Jul-2008.Hendricksen K, Gleason D, Young J, Saltzstein D, Gershman A, Lerner S and Witjes J (2008) Safety and Side Effects of Immediate Instillation of Apaziquone Following Transurethral Resection in Patients With Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 180, NO. 1, (116-120), Online publication date: 1-Jul-2008.Herr H (2007) Low Risk Bladder Tumors—Less is More!Journal of Urology, VOL. 179, NO. 1, (13-14), Online publication date: 1-Jan-2008.Berrum-Svennung I, Granfors T, Jahnson S, Boman H and Holmäng S (2007) A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small RecurrencesJournal of Urology, VOL. 179, NO. 1, (101-106), Online publication date: 1-Jan-2008.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.Soler-Martínez J, Vozmediano-Chicharro R, Morales-Jiménez P, Hernández-Alcaraz D, Vivas-Vargas E, García-Vaquero I and Baena-González V (2007) Holmium Laser Treatment for Low Grade, Low Stage, Noninvasive Bladder Cancer With Local Anesthesia and Early Instillation of Mitomycin CJournal of Urology, VOL. 178, NO. 6, (2337-2339), Online publication date: 1-Dec-2007.Herr H, Donat S and Reuter V (2007) Management of Low Grade Papillary Bladder TumorsJournal of Urology, VOL. 178, NO. 4, (1201-1205), Online publication date: 1-Oct-2007.Koya M, Simon M and Soloway M (2018) Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, VOL. 175, NO. 6, (2004-2010), Online publication date: 1-Jun-2006.BROCKS C, BÜTTNER H and BöHLE A (2018) INHIBITION OF TUMOR IMPLANTATION BY INTRAVESICAL GEMCITABINE IN A MURINE MODEL OF SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 174, NO. 3, (1115-1118), Online publication date: 1-Sep-2005.WOLF J, DASH A, HOLLENBECK B, JOHNSTON W, MADII R and MONTGOMERY J (2018) INTERMEDIATE FOLLOWUP OF HAND ASSISTED LAPAROSCOPIC NEPHROURETERECTOMY FOR UROTHELIAL CARCINOMA:: FACTORS ASSOCIATED WITH OUTCOMESJournal of Urology, VOL. 173, NO. 4, (1102-1107), Online publication date: 1-Apr-2005.Related articlesJournal of Urology9 Nov 2018RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology9 Nov 2018RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS Volume 171Issue 6 Part 1June 2004Page: 2186-2190 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsrecurrencemeta-analysisdrug therapybladder neoplasmsMetricsAuthor Information RICHARD J. SYLVESTER More articles by this author WILLEM OOSTERLINCK More articles by this author ADRIAN P.M. van der MEIJDEN More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2165543889 created "2016-06-24" @default.
• W2165543889 creator A5004584899 @default.
• W2165543889 creator A5073799244 @default.
• W2165543889 creator A5075711884 @default.
• W2165543889 date "2004-06-01" @default.
• W2165543889 modified "2023-10-14" @default.
• W2165543889 title "A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS" @default.
• W2165543889 cites W1968838861 @default.
• W2165543889 cites W1973003019 @default.
• W2165543889 cites W1999771696 @default.
• W2165543889 cites W2051352978 @default.
• W2165543889 cites W2053443109 @default.
• W2165543889 cites W2053644434 @default.
• W2165543889 cites W2055653191 @default.
• W2165543889 cites W2055861457 @default.
• W2165543889 cites W2056633235 @default.
• W2165543889 cites W2087107415 @default.
• W2165543889 cites W2106190198 @default.
• W2165543889 cites W2123614023 @default.
• W2165543889 cites W2126051101 @default.
• W2165543889 cites W2168430786 @default.
• W2165543889 cites W2403817910 @default.
• W2165543889 cites W2417407414 @default.
• W2165543889 cites W40576421 @default.
• W2165543889 cites W4243691565 @default.
• W2165543889 cites W4244617181 @default.
• W2165543889 cites W4317676636 @default.
• W2165543889 doi "https://doi.org/10.1097/01.ju.0000125486.92260.b2" @default.
• W2165543889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15126782" @default.
• W2165543889 hasPublicationYear "2004" @default.
• W2165543889 type Work @default.
• W2165543889 sameAs 2165543889 @default.
• W2165543889 citedByCount "643" @default.
• W2165543889 countsByYear W21655438892012 @default.
• W2165543889 countsByYear W21655438892013 @default.
• W2165543889 countsByYear W21655438892014 @default.
• W2165543889 countsByYear W21655438892015 @default.
• W2165543889 countsByYear W21655438892016 @default.
• W2165543889 countsByYear W21655438892017 @default.
• W2165543889 countsByYear W21655438892018 @default.
• W2165543889 countsByYear W21655438892019 @default.
• W2165543889 countsByYear W21655438892020 @default.
• W2165543889 countsByYear W21655438892021 @default.
• W2165543889 countsByYear W21655438892022 @default.
• W2165543889 countsByYear W21655438892023 @default.
• W2165543889 crossrefType "journal-article" @default.
• W2165543889 hasAuthorship W2165543889A5004584899 @default.
• W2165543889 hasAuthorship W2165543889A5073799244 @default.
• W2165543889 hasAuthorship W2165543889A5075711884 @default.
• W2165543889 hasConcept C121608353 @default.
• W2165543889 hasConcept C126322002 @default.
• W2165543889 hasConcept C126894567 @default.
• W2165543889 hasConcept C141071460 @default.
• W2165543889 hasConcept C143998085 @default.
• W2165543889 hasConcept C146357865 @default.
• W2165543889 hasConcept C151730666 @default.
• W2165543889 hasConcept C168563851 @default.
• W2165543889 hasConcept C2776694085 @default.
• W2165543889 hasConcept C2780352672 @default.
• W2165543889 hasConcept C535046627 @default.
• W2165543889 hasConcept C71924100 @default.
• W2165543889 hasConcept C86803240 @default.
• W2165543889 hasConcept C95190672 @default.
• W2165543889 hasConceptScore W2165543889C121608353 @default.
• W2165543889 hasConceptScore W2165543889C126322002 @default.
• W2165543889 hasConceptScore W2165543889C126894567 @default.
• W2165543889 hasConceptScore W2165543889C141071460 @default.
• W2165543889 hasConceptScore W2165543889C143998085 @default.
• W2165543889 hasConceptScore W2165543889C146357865 @default.
• W2165543889 hasConceptScore W2165543889C151730666 @default.
• W2165543889 hasConceptScore W2165543889C168563851 @default.
• W2165543889 hasConceptScore W2165543889C2776694085 @default.
• W2165543889 hasConceptScore W2165543889C2780352672 @default.
• W2165543889 hasConceptScore W2165543889C535046627 @default.
• W2165543889 hasConceptScore W2165543889C71924100 @default.
• W2165543889 hasConceptScore W2165543889C86803240 @default.
• W2165543889 hasConceptScore W2165543889C95190672 @default.
• W2165543889 hasIssue "6 Part 1" @default.
• W2165543889 hasLocation W21655438891 @default.
• W2165543889 hasLocation W21655438892 @default.
• W2165543889 hasOpenAccess W2165543889 @default.
• W2165543889 hasPrimaryLocation W21655438891 @default.
• W2165543889 hasRelatedWork W167319750 @default.
• W2165543889 hasRelatedWork W1984282923 @default.
• W2165543889 hasRelatedWork W1987468340 @default.
• W2165543889 hasRelatedWork W2003938723 @default.
• W2165543889 hasRelatedWork W2047967234 @default.
• W2165543889 hasRelatedWork W2118496982 @default.
• W2165543889 hasRelatedWork W2439875401 @default.
• W2165543889 hasRelatedWork W2118673085 @default.
• W2165543889 hasRelatedWork W2525756941 @default.
• W2165543889 hasRelatedWork W2903040050 @default.
• W2165543889 hasVolume "171" @default.
• W2165543889 isParatext "false" @default.
• W2165543889 isRetracted "false" @default.
• W2165543889 magId "2165543889" @default.
• W2165543889 workType "article" @default.